Parse Biosciences, a Seattle, WA-based company dedicated to providing scalable single-cell sequencing solutions, raised $41.5M in Series B funding.
The round was co-led by Marshall Wace and Janus Henderson Investors. Soleus Capital, Logos Capital and Bioeconomy Capital also participated in the round, bringing total funding to date to over $50M.
The company intends to use the funds to expand commercialization of its Evercode Whole Transcriptome products, which empower researchers to profile cells at various levels of scale.
Led by Alex Rosenberg, CEO and co-founder, and Charlie Roco, CTO and co-founder, Parse Biosciences is a company with the mission of accelerating progress in human health and scientific research. Its product portfolio includes the Evercode Whole Transcriptome Mega, which can profile up to 1,000,000 cells in parallel, and the Evercode Whole Transcriptome Mini, a kit used to profile up to 10,000 cells in parallel for studies of smaller scale.
Following the raise of their $7M Series A round in January 2021, the company extended its reach on a global scale. In October 2021, Parse partnered with Decode Sciences to provide its single-cell sequencing solution to Australia and New Zealand. Shortly afterwards, Parse announced a distribution agreement with Research Instruments Pte Ltd to expand its availability to Singapore, Thailand, Malaysia and Vietnam.
FinSMEs
15/02/2022